Key terms
About BNTC
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BNTC news
Mar 08
4:33pm ET
Benitec Biopharma Awards Stock Options to Top Executives
Feb 23
4:11pm ET
Benitec Biopharma files $125M mixed securities shelf
Feb 15
6:24am ET
Benitec Biopharma price target raised to $10 from $8 at JMP Securities
Feb 15
12:30am ET
Analysts Are Bullish on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Benitec Biopharma (BNTC)
Jan 24
7:19am ET
Benitec Biopharma price target raised to $8 from $6 at JMP Securities
No recent press releases are available for BNTC
BNTC Financials
Key terms
Ad Feedback
BNTC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BNTC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
